Gilead Sciences (MEX:GILD) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GILD Gilead Sciences Inc MEX:GILD
71 GF Score
Price MXN2,400.00
GF Value MXN1,711.12
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

MEX:GILD
71GF Score
Gilead Sciences Inc MEX:GILD
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gilead Sciences (MEX:GILD) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of MXN2,400.00 is trading 40.3% above its estimated GF Value™ of MXN1,711.12. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for MEX:GILD:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: MXN1,711.12 vs. price of MXN2,400.00 (40.3% above fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the MEX:GILD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
71GF Score

Get the complete analysis for MEX:GILD

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,400.00
Price
MXN1,711.12
GF Value